Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthcare data company with 130K connected physicians; EHR-connected real-world evidence network for pharma analytics rebranded from Allscripts competing with IQVIA for life sciences data.
Veradigm (formerly Allscripts Healthcare) is a healthcare information technology company providing EHR-connected data network services, physician practice management software, pharmacy solutions, and life sciences data analytics — operating at the intersection of clinical care delivery and healthcare data commercialization. Listed on NASDAQ (NASDAQ: MDRX) and headquartered in Chicago, Illinois, Veradigm rebranded from Allscripts in 2023 as it refocused from clinical EHR software toward data and analytics services, generating approximately $600 million in annual revenue.\n\nVeradigm's core asset is its network of approximately 130,000 connected physicians and tens of millions of de-identified patient records accessible through its data products. The Veradigm Network connects ambulatory physician practices running Allscripts EHR (Professional EHR, TouchWorks) and enables data flows for prescription analytics, clinical decision support, and real-world evidence (RWE) for pharmaceutical companies. The life sciences data business provides pharma clients with prescription analytics, patient journey data, and clinical research data services.\n\nIn 2025, Veradigm is in strategic transition — the company has been exploring alternatives to maximize shareholder value, including potential sale or acquisition, following activist investor pressure. The EHR product portfolio (Allscripts-branded physician practice software) competes with athenahealth, Epic, and eClinicalWorks in the ambulatory market, though Veradigm's focus has shifted toward its data network value rather than competing head-to-head in EHR functionality. Veradigm competes with IQVIA, Komodo Health, and Definitive Healthcare for life sciences real-world data. The 2025 strategy focuses on growing the data analytics and real-world evidence business while managing the legacy EHR product base.
$500M Series D at $11B valuation (Feb 2026) — largest voice AI funding round ever. $330M ARR; 1M+ developers using the API. Enterprise customers: Deutsche Telekom, Revolut, Meta, Salesforce. Voices in 32 languages; real-time cloning from 1 second of audio.
ElevenLabs was founded in 2022 by Piotr Dabkowski and Mati Staniszewski, two former Google and Palantir engineers who set out to break the language barrier using AI voice technology. The company specializes in AI-powered voice synthesis, cloning, and dubbing, enabling developers and enterprises to generate human-quality speech in over 30 languages. Its core technology combines deep learning models trained on massive speech datasets to produce natural-sounding voices indistinguishable from real humans.\n\nElevenLabs offers a suite of products including its flagship text-to-speech API, voice cloning tools, and an AI dubbing platform that localizes video content while preserving the speaker's original voice. Its products target a broad audience—from indie developers building audio apps to large enterprises deploying voice interfaces at scale. Key differentiators include ultra-low latency streaming synthesis, fine-grained voice customization, and a growing library of pre-built AI voices across accents and styles.\n\nElevenLabs has grown rapidly, surpassing $330M in annualized revenue and serving over 1 million developers. Enterprise clients include Deutsche Telekom, Spotify, and leading media companies. In February 2026, the company closed a $500M Series D at an $11B valuation, cementing its position as the market leader in AI voice. Its APIs power podcasts, audiobooks, video games, and customer service bots worldwide, making ElevenLabs the default infrastructure layer for AI-generated audio.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.